Johnson & Johnson
NYSE:JNJ

Watchlist Manager
Johnson & Johnson Logo
Johnson & Johnson
NYSE:JNJ
Watchlist
Price: 145.4 USD 0.09%
Market Cap: 350.1B USD
Have any thoughts about
Johnson & Johnson?
Write Note

Johnson & Johnson
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Johnson & Johnson
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Johnson & Johnson
NYSE:JNJ
Income from Continuing Operations
$14.8B
CAGR 3-Years
-6%
CAGR 5-Years
1%
CAGR 10-Years
-2%
Bristol-Myers Squibb Co
NYSE:BMY
Income from Continuing Operations
-$7.2B
CAGR 3-Years
-10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Income from Continuing Operations
$4.3B
CAGR 3-Years
-40%
CAGR 5-Years
4%
CAGR 10-Years
-9%
Merck & Co Inc
NYSE:MRK
Income from Continuing Operations
$12.2B
CAGR 3-Years
27%
CAGR 5-Years
5%
CAGR 10-Years
8%
Zoetis Inc
NYSE:ZTS
Income from Continuing Operations
$2.4B
CAGR 3-Years
7%
CAGR 5-Years
11%
CAGR 10-Years
16%
Eli Lilly and Co
NYSE:LLY
Income from Continuing Operations
$8.4B
CAGR 3-Years
12%
CAGR 5-Years
14%
CAGR 10-Years
12%
No Stocks Found

Johnson & Johnson
Glance View

Market Cap
350B USD
Industry
Pharmaceuticals
Economic Moat
Wide

Founded in 1886, Johnson & Johnson began its journey with a commitment to revolutionizing healthcare, starting with the sterile surgical dressings it produced to reduce infections in hospitals. Over the decades, this vision expanded into a global healthcare powerhouse, intricate in its operation yet unified in its mission to improve lives. Johnson & Johnson's business model is built on three core segments: pharmaceuticals, medical devices, and consumer health products. Each segment harnesses the synergy of innovation, research, and a deep understanding of customer needs. The pharmaceutical division, one of its most robust, thrives on producing treatments for various medical conditions, including immunology, oncology, and neuroscience. It is in this domain that cutting-edge research and development efforts translate into high-margin therapies, driving substantial portions of the company's revenue. Beyond pharmaceuticals, the medical devices segment forms a pillar of Johnson & Johnson's operations, offering a spectrum of products essential for surgeries, orthopedics, and vision care. These devices are integral for modern healthcare practices, with their premium positioning contributing significantly to the company’s financial health. Meanwhile, Johnson & Johnson's consumer health division addresses everyday wellness needs, with iconic brands like Band-Aid, Tylenol, and Neutrogena. This segment leverages global brand recognition and trust to generate steady, albeit lower-margin, income streams. Together, these segments compose a diversified revenue platform, buffered against sector-specific downturns and positioning Johnson & Johnson as a formidable entity in global healthcare markets.

JNJ Intrinsic Value
155.66 USD
Undervaluation 7%
Intrinsic Value
Price

See Also

What is Johnson & Johnson's Income from Continuing Operations?
Income from Continuing Operations
14.8B USD

Based on the financial report for Sep 29, 2024, Johnson & Johnson's Income from Continuing Operations amounts to 14.8B USD.

What is Johnson & Johnson's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-2%

Over the last year, the Income from Continuing Operations growth was 19%. The average annual Income from Continuing Operations growth rates for Johnson & Johnson have been -6% over the past three years , 1% over the past five years , and -2% over the past ten years .

Back to Top